Abstract
Objectives
DIPNECH is a rare pre-neoplastic condition that often presents with a variety of non-specific pulmonary symptoms and sometimes seen in conjunction with pulmonary carcinoid tumors. There are very limited data on use of somatostatin analogs in patients with DIPNECH. We review the long-term outcomes of somatostatin analog therapy with regard to symptom control in patients with DIPNECH.
Materials/Methods
Retrospective study out of our extensive registry of over 2000 neuroendocrine tumors identifies 184 pulmonary neuroendocrine tumors. Out of this, there were five histopathologically confirmed cases of DIPNECH. Appropriate institutional review board permission was taken for this analysis.
Results
All 5 patients were females, with a mean age at diagnosis was 65.5 years. Follow-up period includes 1–5 years. Cough was the presenting complaint in all five patients described as mostly dry, except for one patient who had productive early morning cough. Other symptoms seen in one of our patients included wheezing, flushing, and fluctuating blood pressure. No one reported weight loss, hemoptysis, and shortness of breath. One of our patients had a benign thyroid nodule and two patients had previous history of breast cancer. All five of our patients were histopathologically diagnosed by lung biopsy. 4 out of 5 patients were started on a somatostatin analog. All four patients reported drastic improvement in cough. One patient reported mild abdominal discomfort and diarrhea as side effects but remained on treatment.
Conclusions
From our single institution review of neuroendocrine pulmonary tumor cases, we found only five cases of DIPNECH, which reaffirms rare nature of the pathology. It primarily affects females over 60 years with dry cough as the most common presenting symptom. Most of our patients responded to treatment with a somatostatin analog and had significant improvement in their presenting symptoms. Somatostatin analogs were well tolerated resulting in significant resolution of presenting symptoms in most of our patients. Further research is needed; however, a trial of somatostatin analogs should be considered in the treatment of patients with DIPNECH with responders being treated long term.
Similar content being viewed by others
References
Felton WL, Liebow AA, Lindskog GE (1953) Peripheral and multiple bronchial adenomas. Cancer 6:555–566
Aguayo SM, Miller YE, Waldron JA Jr et al (1992) Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 327:1285–1288
Davies SJ, Gosney JR, Hansell DM et al (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 62:249–252
Aubry MC, Thomas CF Jr, Jett JR, Swensen SJ, Myers JL (2007) Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest 131:1635–1643
Beasley MB, Brambilla E, Travis WD (2005) The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 40:90–97
Gorshtein A, Gross DJ, Barak D, Strenov Y, Refaeli Y, Shimon I, Grozinsky-Glasberg S (2012) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity. Cancer 118(3):612–619
Kerr KM (2001) Pulmonary preinvasive neoplasia. J Clin Pathol 54:257–271
Lee JS, Brown KK, Cool C, Lynch DA (2002) Diffuse pulmonary neuroendocrine cell hyperplasia: radiologic and clinical features. J Comput Assist Tomogr 26:180–184
Ge Y, Eltorky MA, Ernst RD, Castro CY (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Ann Diagn Pathol 11:122–126
Adrienne A, Nassar MD et al (2011) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. A systematic overview. Am J Respir Crit Care Med 184(1):8–16. doi:10.1164/rccm.201010-1685PP
Zhou H, Ge Y, Janssen B et al (2014) Double lung transplantation for diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. J Bronchol Interv Pulmonol 21(4):342–345
Jones MH, Wales D et al (2013) Diffuse idiopathic pulmonary endocrine cell hyperplasia (DIPNECH) requiring bilateral sequential lung transplant. Eur Respir J 42(Suppl 57):P2179
Anthony L, Freda PU (2009) From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 25:2989–2999
Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733–1742
Bousquet C et al (2012) Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 97:727–737
Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592–1599
Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S, Bousquet C (2014) Somatostatin analogs:does pharmacology impact antitumor efficacy? Trends Endocrinol Metab 25(3):115–127
Pyronnet S et al (2008) Antitumor effects of somatostatin. Mol Cell Endocrinol 286:230–237
Laklai H et al (2009) Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci USA 106:17769–17774
PROMID Study Group, Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Clin Oncol 27(28):4656–4663. doi:10.1200/JCO.2009.22.8510
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Robert A. Ramirez is a consultant for bioTheranostics Inc. No financial support was obtained for our study. The authors had full control of the design of the study, methods used, outcome parameters and results, analysis of data, and production of the written report. Aman Chauhan has no conflict of interest.
Rights and permissions
About this article
Cite this article
Chauhan, A., Ramirez, R.A. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series. Lung 193, 653–657 (2015). https://doi.org/10.1007/s00408-015-9754-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-015-9754-2